This article is an accurate and unbiased description of the findings of a study published in the reliable journal Nature Medicine, called "Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial" by Huang et al.

The study found that improved progression-free survival was seen in patients who received immunotherapy earlier in the day.

The article presents balanced views of other experts, that these findings need to be replicated in other populations before they can be 100% believed. It also highlights other studies which agree that timing does influence immune system activity.

This article was written on 6th February 2026. After its publication, on 19th February 2026, the study by Huang et al. started being investigated by editors of the journal, due to differences in the originally planned study method (written about on https://clinicaltrials.gov/study/NCT05549037 ) vs. the method published in the Nature Medicine paper. Therefore, the findings of this study should be taken with a pinch of salt, until the investigation is resolved.

As a cancer researcher studying non-small cell lung cancer (NSCLC), I thought the technical terminology and definitions used in this article were accurate.